Advertisement


Sarat Chandarlapaty, MD, PhD, on BOLERO-2 Clinical Trial Results

2015 San Antonio Breast Cancer Symposium

Advertisement

Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who had a D538G and/or a Y537S mutation in the ESR1 gene had significantly worse median overall survival (Abstract S2-07).



Related Videos

Breast Cancer

Michael Gnant, MD, on Hormone Receptor–Positive Breast Cancer: Results From the ABCSG-18 Trial

Michael Gnant, MD, of the Medical University of Vienna, discusses a study in which denosumab was added to adjuvant aromatase inhibitor therapy to improve disease-free survival in p...

Breast Cancer

Judy E. Garber, MD, MPH, on Clinical Applications of Hereditary Multigene Panels

Judy E. Garber, MD, MPH, of the Dana-Farber Cancer Institute, gives her expert perspective on this vital and timely topic.

Breast Cancer

Andrew Seidman, MD, and Hope Rugo, MD, on Advanced Breast Cancer: KEYNOTE-028 Study Results

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Hope S. Rugo, MD, of the University of California, San Francisco, discuss preliminary efficacy a...

Breast Cancer

Matthew J. Ellis, PhD, FRCP: Update on Translational Research

Matthew J. Ellis, PhD, FRCP, of the Baylor College of Medicine, gives his expert perspective on this evolving area of research.

Breast Cancer

Andrew Seidman, MD, and Eric Winer, MD, on Triple-Negative Breast Cancer: Results of the CALGB Alliance Trial

Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Eric P. Winer, MD, of the Dana-Farber Cancer Institute, discuss the results of this study that s...

Advertisement

Advertisement



Advertisement